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Abstract
Background: The enzyme dihydropteroate synthase (DHPS) participates in the de novo synthesis of folate cofactors
by catalyzing the formation of 7,8-dihydropteroate from condensation of p-aminobenzoic acid with 6-
hydroxymethyl-7,8-dihydropteroate pyrophosphate. DHPS is absent from humans, who acquire folates from diet,
and has been validated as an antimicrobial therapeutic target by chemical and genetic means. The bacterium
Burkholderia cenocepacia is an opportunistic pathogen and an infective agent of cystic fibrosis patients. The
organism is highly resistant to antibiotics and there is a recognized need for the identification of new drugs
against Burkholderia and related Gram-negative pathogens. Our characterization of the DHPS active site and
interactions with the enzyme product are designed to underpin early stage drug discovery.
Results: An efficient recombinant protein expression system for DHPS from B. cenocepacia (BcDHPS) was prepared,
the dimeric enzyme purified in high yield and crystallized. The structure of the apo-enzyme and the complex with
the product 7,8-dihydropteroate have been determined to 2.35 Å and 1.95 Å resolution respectively in distinct
orthorhombic crystal forms. The latter represents the first crystal structure of the DHPS-pterin product complex,
reveals key interactions involved in ligand binding, and reinforces data generated by other structural studies.
Comparisons with orthologues identify plasticity near the substrate-binding pocket and in particular a range of
loop conformations that contribute to the architecture of the DHPS active site. These structural data provide a
foundation for hit discovery. An intriguing observation, an artifact of the analysis, that of a potential sulfenamide
bond within the ligand complex structure is mentioned.
Conclusion: Structural similarities between BcDHPS and orthologues from other Gram-negative species are evident
as expected on the basis of a high level of sequence identity. The presence of 7,8-dihydropteroate in the binding
site provides details about ligand recognition by the enzyme and the different states of the enzyme allow us to
visualize distinct conformational states of loops adjacent to the active site. Improved drugs to combat infections by
Burkholderia sp. and related Gram-negative bacteria are sought and our study now provides templates to assist that
process and allow us to discuss new ways of inhibiting DHPS.
Background
Dihydropteroate synthase (DHPS, EC: 2.5.1.15) catalyses
the reaction of 6-hydroxymethyl-7,8-dihydropterin-pyro-
phosphate with p-aminobenzoic acid (p-ABA) to yield
7,8-dihydropteroate and pyrophosphate (Figure 1). In so
doing the enzyme supports the biosynthesis of folate, a
key metabolite required to support the synthesis of
DNA, and proteins. The provision of folates, either by
synthesis in plants and microorganisms or as acquired
in the diet by mammals, supports life. The folate biosyn-
thetic pathway is absent from humans and contains sev-
eral highly valued drug targets for treatments of
numerous infections [1,2]. The folate pathway consists
of a number of enzymes in addition to DHPS, including:
6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
(HPPK), dihydrofolate synthetase (DHFS) and dihydrofo-
late reductase (DHFR). Drugs that inhibit DHFR and
DHPS are used in the treatment of infections by the api-
complexan parasites Plasmodium sp. and Toxoplasma
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tional enzyme fused to HPPK [5].
The Gram-negative aerobic bacterium Burkholderia
cenocepacia is an opportunistic pathogen and a member
of the Burkholderia complex, a closely related group of
bacteria, which cause particular problems for cystic
fibrosis patients [6]. Other members of the genus are
also pathogenic; B. pseudomallei is the causal agent for
melioidosis [7], a serious infection found primarily in
South East Asia, and B. mallei is responsible for glan-
ders, an infection of livestock [8]. A characteristic of
Burkholderia species, and one that makes them particu-
larly troublesome pathogens is that they are highly resis-
tant to a wide range of antibiotics [9-12].
DHPS is a validated drug target for the treatment of
diseases caused by bacteria and protozoan parasites
[1,2]. Sulfonamides in particular are inhibitors of this
enzyme and are used as antibiotics [13]. However,
increasing levels of resistance to sulfonamides has been
observed and there is a need for new drugs to compen-
sate for this [9,14-17]. The value of accurate structural
information to support early stage drug discovery is well
recognized [18] and characterization of the active site of
DHPS from pathogenic organisms has the potential to
support the design of new treatments.
Structures of DHPS from Gram-negative and Gram-
positive bacteria have been reported [19-23] and also
the bifunctional HPPK-DHPS from Saccharomyces cere-
visiae and Francisella tularensis [24,25]. The structural
studies extend to characterization of the oxidized pro-
duct analogue, pteroic acid, and a series of pterin deriva-
tives in complex with Bacillus anthracis DHPS
(BaDHPS) [21,26] and also a series of pterin derivatives,
and a complex of Escherichia coli DHPS (EcDHPS) with
sulfanilamide [19]. One structure, that of Thermus ther-
mophilus DHPS complexed with p-ABA has also been
solved [Protein Data Bank (PDB) ID: 2DZA]. One
observation, reported in several studies [e.g. [20]] and
made by our inspection of PDB entries is the pro-
nounced conformational flexibility of loops around the
active site. This has resulted in the omission of impor-
tant residues from the structural models.
Here we report the expression, purification and crys-
tallization of BcDHPS. We describe the crystal struc-
tures of the apo-enzyme, the first complex with the
actual enzyme product 7,8-dihydropteroate, which pro-
duces a more complete view of the active site than most
other structures, similarities and differences between
DHPS structures, and discuss molecular features that
might be exploited to derive novel inhibitors.
Results and Discussion
General comments
An efficient recombinant source of BcDHPS was pre-
pared and a purification protocol established that
resulted in approximately 20 mg of pure enzyme from
one litre of bacterial culture. The purified protein was
used in co-crystallization screens with the inhibitor
sulphadoxine or the enzyme product 7,8-dihydroptero-
ate. Distinct orthorhombic crystal forms were obtained.
However, analysis of the crystals grown in the presence
of sulphadoxine revealed only water molecules in the
active site and this therefore represents the apo-
BcDHPS structure determined to 2.35 Å resolution.
The structure of BcDHPS complexed with 7,8-dihy-
dropteroate was refined to 1.95 Å resolution. Initial
phases for the product complex were obtained by
molecular replacement calculations using the EcDHPS
structure [PDB ID: 1AJ2, [19]], which has 44% amino
acid sequence identity to BcDHPS, as the search
model. The model for molecular replacement calcula-
tions to solve the apo-structure of BcDHPS was the
product complex. BcDHPS comprises 292 amino acids.
The apo-enzyme crystallized in space group
C222
1 with
Figure 1 The reaction catalyzed by dihydropteroate synthase. 7,8-dihydropterin pyrophosphate reacts with p-aminobenzoic acid (p-ABA) to
yield 7,8-dihydropteroate and pyrophosphate.
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residues could not be modeled in the electron density
maps and so were omitted hence the model for this
structure consists of 268 residues. The crystals for the
complex structure display space group P212121 and
there are two molecules, labeled A and B, in the asym-
metric unit. Here also disorder was evident and several
residues in each subunit are missing from the model.
Subunit A consists of 280 residues and subunit B con-
sists of 281. These subunits are similar in structure
and superimpose with an r.m.s.d. of 0.34 Å (over 280
aligned Ca a t o m s ) .T h et w os t r u c t u r e ss u p e r i m p o s e
with an r.m.s.d. of 0.37 Å (over 268 aligned Ca atoms,
superimposing subunit A of the complex structure).
Such a close agreement suggests that there are no
gross structural changes upon ligand binding but as
will be explained, ligand binding promotes greater
order in loops that contribute to the active site.
The Overall Structure and comparison with orthologues
BcDHPS displays a triosephosphate isomerase (TIM)-
barrel fold, consisting of eight parallel b-strands sur-
rounded by eight a-helices (Figure 2). At the N-termi-
nus there is an antiparallel alignment of two short b-
strands, termed Nb1a n dN b2, linked by a tight turn.
This is a feature common to some other DHPS struc-
tures. We assign b1a st h ef i r s ts t r a n do ft h eb8:a8 bar-
rel. Residues 234-242 form a short a-helix inserted
between b7a n da8 and is considered part of loop 7.
Size-exclusion gel filtration indicates that BcDHPS is a
dimer, of approximate mass 68 kDa, in solution (data
not shown). The apo-enzyme structure has a single
polypeptide chain in the asymmetric unit whilst the pro-
duct complex has two. In the latter structure, chains A
and B form a dimer stabilized by an interface with a
surface area (~1,200 Å
2) that is approximately 10% of
that of a single subunit (~12,000 Å
2). Residues on a9o f
one subunit interact with residues on a6, a7a n da8o f
the partner subunit. Nearly 40 amino acids from each
subunit participate in around 20 direct hydrogen bonds
and salt bridge interactions, plus numerous water
mediated contacts between the subunits and The same
dimer is formed in the apo-structure by the symmetry
operation -x, y, -z + ½.
The alignment of the central b-strands results in the
localization of the N-terminal segments of these strands
at one end of the barrel and the C-terminal segments at
the other. On the N-terminal side there are polypeptide
segments that form loops connecting the a-helix to the
b-strand that follows. These loops are relatively short
and well defined in the electron density maps (data not
shown). On the C-terminal side of the TIM-barrel,
where the active site is located, there are longer, more
flexible loops, called the C-terminal loops, that link a b-
strand with the following a-helix. The shorter N-term-
inal loops of TIM-barrel structures are suggested to
contribute stability of the protein fold whereas the C-
terminal loops contribute to enzyme activity by creation
of the active site [27]. The first C-terminal loop, linking
b1t oa1 could not be modeled in either structure, due
to poorly defined density, suggesting a significant degree
of conformational flexibility. Modeling of loop 2, linking
b2t oa2 was possible only in the case of the product
complex. The increased order observed for the complex
is consistent with the stabilizing effects of ligand bind-
ing, as loop 2 contributes to the active site, a feature
that will be discussed later.
The overall sequence identity of BcDHPS with the
enzyme from other Gram-negative species is in the
region of 40-60% and the fold of BcDHPS and dimeric
quaternary structure is consistent with that observed for
DHPS from other species. Structural overlays of the
BcDHPS subunit with orthologous structures identified
greatest similarity to E. coli DHPS with r.m.s.d. values of
1.35-1.37 Å [PDB IDs: 1AJ0, 1AJZ and 1AJ2, values
given for the complex subunit A, over 264, 264 and 263
aligned Ca atoms]. R.m.s.d. values of 2.1 Å (for both
subunit A and B, over 242 (A) and 239 (B) aligned Ca
atoms) were observed for DHPS structures from Strepto-
coccus pneumoniae [PDB IDs: 2VEF and 2VEG] and 1.5
Å (value for subunit A, over 239 aligned Ca atoms) for
the Mycobacterium tuberculosis DHPS structure [PDB
ID: 1EYE]. The orientation of DHPS subunits with
respect to each other varies [20] but there is no evi-
dence to suggest that this has an influence on activity.
The DHPS active site is formed entirely within a single
subunit. The difference in subunit orientation may sim-
ply reflect sequence variation between species. The resi-
dues that occur at the dimer interface (on a6, a7, a8
and a9) show only a low level of sequence conservation
(Figure 3).
Figure 2 The structure of BcDHPS and BcDHPS complex.T h e
overall structure of the BcDHPS dimer with 7,8-dihydropteroate
bound. a-helices are shown in red and b-sheets in blue, with C
atoms of the ligand 7,8-dihydropteroate shown in yellow.
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the most structural variation between DHPS models has
been observed. Of particular note are loops 1 and 2.
The amino acid residues that comprise these loops are
highly conserved in DHPS orthologues (Figure 3) but
they are absent from the majority of published crystallo-
graphic models. Where the electron density maps have
allowed for their inclusion it is noted that the polypep-
tides display different conformations. This points to a
high propensity to disorder due to flexibility and an
important role in enzyme function. One role for these
loops has been proposed, namely that they close over
and shield the active site from bulk solvent during cata-
lysis [20]. To this we would add a potentially important
thermodynamic contribution to the enzyme function.
Changes in conformational entropy associated with dis-
tinct configurations of the loop structures might contri-
bute to the free energy of protein-ligand association
[28]. We note the presence of conserved glycine residues
at the C-terminal end of b1 and on loop 2 itself (Figure
3) that may contribute to the flexibility in this part of
the structure. Loop 2 is closer than loop 1 to the
enzyme active site and adjacent to loop 5 (Figure 4).
The residues that constitute loop 5 are less well con-
served (Figure 3). BcDHPS has 17 residues in this loop,
a similar number, 16, are present in the E. coli enzyme,
whilst Staphylococcus aureus DHPS has only 9 residues
in the loop (Figure 3). This lack of conservation in loop
5 and interactions with the conformationally labile loop
2 likely contributes to the variation observed when dif-
ferent DHPS structures are compared (Figure 4).
As an aside we mention the following observation
made by a reviewer. At the C-terminal end of b1, lead-
ing into loop 1 the amino acid sequence in BcDHPS
Asn28-Ala29-Thr30. In EcDHPS and SaDHPS the
sequence is Asn-Val-Thr. This is a well-recognized N-
glycosylation signal, Asn-X-Ser/Thr [29]. However, in
each case DHPS is a cytosolic bacterial enzyme from
organisms lacking in glycosides.
Binding of 7,8-dihydropteroate
The active site of DHPS is positioned at the C-terminal
end of the central b-barrel. Here, the product of the
enzyme reaction, 7,8-dihydropteroate is ordered (Figure 5),
Figure 4 The variations in the positions of active site loops
across three DHPS structures. Superposition of the structures of
BcDHPS with 7,8-dihydropteroate bound (blue), EcDHPS with 7,8-
dihydropterin pyrophosphate bound (green, [PDB ID: 1AJ2]) and
SaDHPS with 6-hydroxymethylpterin-diphosphate bound (violet,
[PDB ID: 1AD4]).
Figure 3 Sequence alignment of three dihydropteroate synthases. The amino acid sequences for DHPS from B. cenocepacia, E. coli and S.
aureus are aligned. The secondary structure relating to BcDHPS is shown colored as in Figure 2. Those residues shaded in black are conserved in
all three sequences and grey marks conservation in two of the three.
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the p-ABA moiety pointing out towards the surface of the
protein (Figure 2). Residues located on strands b3, b4, b6,
b7a n db8 participate in interactions with the product. The
interactions formed between the enzyme and the ligand
are very similar in both subunits and therefore only details
of subunit A are presented (Figure 6) unless stated
otherwise.
The ligand possesses nine functional groups of which
eight participate in direct hydrogen bonds with DHPS.
Four hydrogen bond donors, N2, N3, N8 and N14 inter-
act with functional groups on Asn120, Asp191, Asp101
and Thr68 respectively. The N1 atom of the ligand
accepts a hydrogen bond donated by Asn120 ND2. On
the other side of the pterin, O4 and N5 accept hydrogen
bonds donated from Lys233 NZ. This lysine side chain
is also held in place by a hydrogen bond donated to the
carbonyl oxygen of Gly229. An ordered water molecule
interacts with O4 and Asp191 OD1. A carboxylate oxy-
gen, on the p-ABA moiety, accepts hydrogen bonds
donated from the main chain amide and side chain
hydroxyl groups of Ser234. In subunit A the other oxy-
gen interacts with two water molecules that in turn
interact with the carbonyl and amide groups of Gly195
and Met235 respectively (data not shown). In subunit B
only the latter interaction is observed. The proximity of
C7 to the carbonyl oxygen and OG1 hydroxyl of Thr68,
distances range from 3.1 Å to 3.5 Å in subunits A and
B, indicates the potential for C-H￿￿￿Oh y d r o g e nb o n d s .
These are weak but not insignificant stabilizing interac-
tions [30]. The E. coli DHPS structure [PDB ID: 1AJ2]
with 7,8-dihydropterin pyrophosphate bound in the
active site, shows Thr62 (the equivalent of Thr68 in
BcDHPS) interacting with the phosphate groups of the
ligand [19]. In our BcDHPS structure Thr68, part of
loop 2, interacts with Asp101 and the dihydropterin.
This suggests that the conformation of loop 2 alters
depending on which ligand is bound in the active site.
The pterin is sandwiched between a cluster of hydro-
phobic residues (Ile122, Met144 and Phe196) on one
side (Figure 6) and the guanidinium group of Arg268 on
the other (data not shown). A salt-bridge interaction
between Arg268 and Asp62 helps to determine the
structure in this part of the active site and Asp62 also
interacts with the side chain of Asn120 (data not
shown).
The structure of BaDHPS in complex with pteroic
acid [21] shares most of the key interactions described
above. A notable difference between pteroic acid and
7,8-dihydropteroate is that N8 in the latter is a hydrogen
bond donor, in the former a hydrogen bond acceptor.
The distances between N8 and the carboxylate of the
conserved Asp101 in both structures are close to 3.2 Å.
This suggests to us that in the BaDHPS ligand complex
Asp101 is likely protonated.
Sulfonamides, which are used to treat infections by
Burkholderia [31], inhibit DHPS by binding in the p-
ABA binding site, as shown through competition, resis-
tance and structural data [19,20,22]. The complex of
EcDHPS with sulfanilamide showed the ligand posi-
tioned between Lys221 and Arg63. This is similar to the
placement of the p-ABA groups in the pteroic acid and
Figure 6 The BcDHPS binding site of 7,8-dihydropteroate.
Potential hydrogen bonds formed between N and O atoms are
depicted as blue dashed lines. C-H￿￿￿O interactions involving C12 as
black dashed lines. The ligand is colored as in Figure 5. C atoms of
DHPS are colored gray, the S atom of Met144 yellow.
Figure 5 The omit electron density associated with 7,8-
dihydropteroate. The blue chicken wire represents the Fo-Fc omit
map contoured at 2.5s. The ligand is colored according to atom
type; C yellow, N blue, O red.
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2. Mutations in residues that contribute to loop 2 have
been noted to correlate with resistance to sulfonamide
and dapsone; in particular the equivalent residues to
Thr68 in BcDHPS [19,20]. The alignment of three bac-
terial DHPS sequences (Figure 3) shows that positions
equivalent to 234 in our structure are occupied either
with serine or arginine. Given that Ser234 interacts with
the p-ABA moiety the difference between serine and
arginine has interesting implications regarding differ-
ences in ligand binding sites across species.
The availability of high-resolution crystal structures
offers opportunities to exploit structure-based methods
to derive information on DHPS inhibitors that would
support early stage drug discovery. The pterin binding
pocket of DHPS is highly conserved across species. In
the enzyme:product complex for BcDHPS we described
the contributions of 14 amino acids above; ten of these
residues are strictly conserved (Figure 3) and two,
Gly229 and Met235, only use main chain functional
groups to bind the 7,8-dihydropteroate. The structures
clearly reveal the necessity for a planar entity and the
arrangement of hydrogen bond donors and acceptors
required to optimize interactions in the pterin binding
pocket. The presence of an ordered water molecule
mediating interactions between the ligand the enzyme
suggests a position where a new hydrogen bonding
interaction might be sought. Unfortunately the disorder
(flexibility) of loop 2 means that many of the crystal
structures have limitations with respect to drug design.
We were fortunate that the product complex of
BcDHPS allowed us to model loop 2 and the complete
structure we obtained provides an improved template
suited for in silico screening. We recognize that there is
flexibility around the edge of the active site part of the
binding site and that this flexibility might make an
important thermodynamic contribution to DHPS func-
tion. This observation suggests that ligands able to inter-
act with and reduce conformational freedom of loop 2
have the potential to increase the free energy of ligand
binding, as might substrate, and these could provide sui-
table chemical matter for future development.
A Potential Cys-Arg Sulfenamide Bond
During refinement of the BcDHPS:dihydropteroate com-
plex we noted an unusual feature in, first the electron
density surrounding the side chains of Cys258 and
Arg262, and then in omit difference maps that is worthy
of mention. The density suggested the possibility of a
covalent linkage, possibly a sulfenamide bond between
Cys258 SG and Arg262 NH2 (Figure 7). The crystallo-
graphic analysis of the apo-enzyme clearly showed the
normal side chains not interacting with each other (Fig-
ure 8). Our first assessment was that conformational
flexibility had produced a mixture of rotamers that were
overlapping. However, there is no evidence of an alter-
native rotamer for either residue. We were surprised
that the feature was conserved in each subunit of the
asymmetric unit and sought data to identify if an unu-
sual covalent linkage was present. The analysis of freshly
purified protein solution using Fourier Transform Ion
Cyclotron Resonance mass spectrometry and Top-Down
fragmentation failed to find any evidence for an unusual
S-N covalent linkage. Similarly analysis of DHPS crys-
tals, from the same batch of protein that gave the com-
plex structure, by trypsin cleavage followed by mass
spectrometry did not find any evidence to substantiate
S-N bond formation.
These residues are located towards the C-terminal end
of a8, at the surface of the protein and contribute to
the dimer interface. The residues are not conserved in
Figure 7 The positions of Cys258 and Arg262 in the product
complex. The blue chicken wire represents the Fo-Fc omit map
contoured at 3.5s.
Figure 8 The positions of Cys258 and Arg262 in apo-BcDHPS.
The blue chicken wire represents the Fo-Fc omit map contoured at
3.5s.
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siologically relevant. A covalent modification may have
occurred due to the experimental conditions in this par-
ticular instance and would likely have followed from
oxidation of the cysteine.
Conclusion
The structure of B. cenocepacia DHPS has been solved
in the presence and absence of a product from the reac-
tion that it catalyses, 7,8-dihydropteroate. These struc-
tures closely resemble published DHPS structures from
other species. Loop 2 has been modeled in the BcDHPS
product complex. This loop, which is highly conserved
in terms of amino acid sequence and inherently flexible,
makes important contributions to the creation of the
active site. The structure of the BcDHPS:7,8-dihydrop-
teroate complex, with loop 2 modeled provides a useful
template to aid the design of new inhibitors of this
enzyme.
Methods
Protein expression and purification
The gene encoding BcDHPS [UniProtKB Q1BXC8] was
amplified from genomic DNA (Belgian Co-ordinated
Collections of Micro-organisms, bacteria collection
(BCCM/LMG)) using 5’-CATATGTCCCCGTTCCT
TCCCGC-3’ and 5’-GGATCCTTATCGTTGCCGC
GCGGCT-3’ as the forward and reverse primers respec-
tively (Thermo Scientific). The restriction sites for NdeI
and BamHI are in bold. The PCR product was ligated
into pCR2.1-TOPO using the TOPO
® TA Cloning
® Kit
(invitrogen) and cloned into a modified pET15b (Nova-
gen) expression vector. This vector produces the protein
with a N-terminal hexa-His tag with a Tobacco Etch
Virus (TEV) protease cleavage site. DNA sequencing
confirmed the identity of the construct and the vector
was heat-shock transformed into E. coli BL21 (DE3)
cells for expression.
Cells were grown at 37°C in 1 L of Luria-Bertani
media supplemented with carbenicillin (50 μgL
-1). Gene
expression was induced, once an OD600 of 0.6 was
reached, by addition of 1 mM isopropyl-b-D-thiogalac-
topyranoside. The culture was maintained for a further
16 hours at 22°C. Cells were harvested by centrifugation
at 3,500 g for 30 min at 4°C.
The cells were resuspended into a lysis buffer (20 mL,
50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 25 mM imida-
zole) containing DNAse I (0.2 mg) and two tablets of a
cocktail of EDTA-free protease inhibitors (Roche) and
lysed using a French press at 16,000 psi. The resultant
lysate was centrifuged at 35,000 g for 30 min at 4°C and
the supernatant loaded onto a pre-equilibrated HisTrap
HP 5 mL column (GE Healthcare) pre-charged with Ni
2
+. A linear gradient of imidazole, 25 mM to 1 M was
applied to elute BcDHPS and the fractions were ana-
lyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis. The BcDHPS containing samples were
pooled and incubated with His-tagged TEV protease (2
m g )a t3 0 ° Cf o r3h o u r sa n dt h e nd i a l y z e di n t o5 0m M
T r i s - H C l ,p H7 . 5 ,2 5 0m MN a C l .T h ep r o t e i nw a s
loaded onto a HisTrap HP 5 ml column and eluted as
described above, untagged BcDHPS did not bind to the
column. A Superdex 200 26/60 size exclusion column
(GE Healthcare) equilibrated with 50 mM Tris-HCl, 250
mM NaCl pH 7.5 was used to further purify the protein.
This column had previously been calibrated with mole-
cular weight standards, blue dextran (>2,000 kDa), thyr-
oglobulin (669 kDa), ferritin (440 kDa), aldolase (158
kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbo-
nic anhydrase (29.5 kDa), ribonuclease A (13.7 kDa) and
aprotinin (6.5 kDa); (GE Healthcare; data not shown).
The protein eluted with one peak of a mass of
approximately 68 kDa corresponding to a dimer. Frac-
tions containing the protein were pooled and concen-
trated using Amicon Ultra devices (Millipore) to 30 mg
L
-1 for subsequent use. The purity and identity of the
protein was further confirmed by matrix-assisted laser
desorption/ionization mass spectrometry, with a yield of
approximately 20 mg L
-1 of cell culture.
Crystallization and data collection
Crystallization conditions were screened using the sitting
drop vapor diffusion method in 96-well plates. This was
achieved with a Phoenix liquid handling system (Rigaku,
Art Robins Instruments) and the commercially available
screens Classics (Qiagen) and JCSG+ (Molecular Dimen-
sions). Optimized conditions were achieved using hang-
ing drop vapor diffusion methods with drops consisting
of 1 μL protein solution and 1 μL reservoir solution.
Crystals of apo-BcDHPS were obtained with reservoir
conditions of 0.3 M Tris-HCl, pH8 and 10% polyethy-
lene glycol (PEG) 8000 and protein solution with
BcDHPS at 7.5 mg mL
-1 and sulphadoxine (2 mM;
Sigma-Aldrich). Rectangular crystals with approximate
dimensions 0.2 mm × 0.2 mm × 0.15 mm grew in one
week. A specimen was transferred to a mixture of reser-
voir solution and 40% PEG 400, for approximately 15
seconds, then transferred into a stream of cold nitrogen
(-170°C) and a data set collected.
Crystals of the complex were obtained with reservoir
conditions of 0.1 M Tris-HCl pH 8, 10% PEG 8000, 0.3
M MgCl2. The protein solution (7.5 mg mL
-1) was incu-
bated at 4°C for 4 hours with 7,8-dihydropteroate (2
mM; Schircks Laboratories). The crystals consisted of
multiple plates with dimensions 0.2 mm × 0.2 mm ×
0.10 mm. A fragment of a crystal, of dimensions 0.1
mm × 0.1 mm × 0.05 mm. was transferred to a mixture
of the reservoir solution and 25% ethylene glycol prior
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was collected.
Data for both crystals were collected in-house with a
Micromax 007 rotating anode generator (copper Ka, l
=1 . 5 4 1 8Å )a n dR - A X I SI V
++ dual image plate detector
(Rigaku). Processing and scaling of the data was carried
o u tu s i n gM O S F L M[ 3 2 ]a n dS C A L A[ 3 3 ] .T h ea p o -
BcDHPS crystal belonged to space group C2221,w i t h
unit cell parameters a = 73.9 Å, b = 89.43 Å, c = 87.60
Å, a = b = g = 90 °. There is one subunit in the asym-
metric unit with VM values of 2.3 Å
3 Da
-1 and a solvent
content of approximately 50%.
The crystal of the BcDHPS:7,8-dihydropteroate com-
plex displayed space group P212121, with unit cell para-
meters a = 73.66 Å, b = 86.92 Å, c = 88.79Å, a = b = g
= 90 °. Two subunits in the asymmetric unit gives VM
of 2.3 Å
3 Da
-1 and solvent content of approximately
50%. The complex structure was solved in PHASER [34]
using molecular replacement with the E. coli DHPS
structure [PDB ID: 1AJ2]. The structure of apo-BcDHPS
was solved using the complex structure for molecular
replacement. Alteration of the model, including addition
of solvent molecules was achieved in COOT [35]. The
model was refined using REFMAC5 [36] with non-crys-
tallographic symmetry (NCS) restraints in the initial
rounds of refinement. Translation, libration, screw ana-
lysis (TLS) was also applied [37]. Crystallographic statis-
tics are presented in Table 1. R.m.s.d. values comparing
the previously published structures were achieved using
DALI [38]. The figures were prepared with PyMOL [39].
Amino-acid sequence alignments were carried out using
the program MUSCLE [40]. The analysis of the dimer
interface used the PISA server [41].
Protein Data Bank accession numbers
Coordinates and structure factors have been deposited
with accession code 2Y5J (apo-enzyme) and 2Y5S (pro-
duct complex).
Abbreviations
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